Unknown

Dataset Information

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.


ABSTRACT:

Background

Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine. CD39 is expressed by different immune cell populations as well as cancer cells of different tumor types and supports the tumor in escaping immune recognition and destruction. Thus, increasing extracellular ATP and simultaneously reducing adenosine concentrations in the tumor can lead to effective anti-tumor immunity.

Methods

We designed locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) with specificity for human or mouse CD39 that do not need a transfection reagent or delivery system for efficient target kn

SUBMITTER: Kashyap AS 

PROVIDER: S-EPMC6419472 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature